I compliment Pan et al. ([@R1]) on their important publication (March 2020) reporting a high incidence of digestive symptoms associated with COVID-19 infection among 204 patients hospitalized, between January and February 2020 at 3 Chinese hospitals, of whom 29 patients (14.2%) had diarrhea as their chief complaint. They associated the presence of any digestive symptom (anorexia, diarrhea, vomiting, or abdominal pain) with higher COVID-19 mortality but did not quantify the diarrhea and did not investigate the pathophysiology of morbidity/mortality from diarrhea. Although pulmonary complications of COVID-19 infection are well recognized, diarrhea is insufficiently characterized. A novel case is reported of moderately severe COVID-19 associated diarrhea that produced electrolyte derangements, dehydration, and likely prerenal kidney injury.

A 41-year-old African American woman was referred to gastroenterology for moderately severe diarrhea (7 to 10 watery, light brown, blood-tinged, bowel movements per day) associated with cough, sneezing, rhinorrhea, mild vomiting, and low-grade pyrexia for 4 days. Medical history included chronically taking rivaroxaban for prior transverse sinus thrombosis; no history of alcoholism, drug abuse, recent travel, or antibiotic use; and no known pulmonary, renal, gastrointestinal, or liver diseases. Patient had diabetes mellitus treated with metformin, hypertension treated with metoprolol, and untreated hypertriglyceridemia and hypercholesterolemia, probably all from metabolic syndrome associated with severe obesity (body mass index = 37 kg/m^2^). Patient was potentially exposed to COVID-19 from working as a nurse\'s aid. She had been vaccinated against influenza 4 months earlier.

Physical examination revealed a blood pressure of 125/77 mm Hg, pulse of 103/minute with orthostasis, temperature of 38.2 °C, respiratory rate of 20 breaths/minute, and O~2~ saturation of 97% on room air. Physical examination revealed rhinitis, decreased skin turgor and absent axillary sweat, lung fields clear to auscultation and percussion, minimal diffuse abdominal tenderness, no hepatosplenomegaly, and guaiac positive stool. Potassium was 3.0 nmol/L (normal: 3.5--5.2 nmol/L), with no electrocardiographic abnormalities, sodium was 132 mmol/L (normal: 135--145 mmol/L), chloride was 94 mmol/L (normal: 98--111 mmol/L), creatinine was 1.24 mg/dL (normal: 0.50--1.10 mg/dL), and blood urea nitrogen was 17 mg/dL (normal: 7--25 mg/dL). The erythrocyte sedimentation rate was 64 (normal: 0--18 mm/hr), and C-reactive protein was 155.5 mg/dL (normal: 0--7.9 mg/dL). Urine specific gravity was 1.029 (\>1.015 consistent with dehydration). Urinalysis and urine culture revealed no urinary tract infection. Hemoglobin was 12.0 g/dL (normal: 12.1--15.0 g/dL) with normocytic indices, and leukocyte count was 3.8 bil/L (normal: 3.3--10.7 bil/L), with normal differential. Aspartate aminotransferase was 53 U/L (normal: 0--34 U/L), and alanine aminotransferase was 64 U/L (normal: 8--37 U/L), with normal other liver function tests. Hepatic serologies were negative for hepatitis A, B, and C. Right upper quadrant ultrasound demonstrated fatty liver.

Chest roentgenogram revealed no pulmonic infiltrates. Tests for influenza A and B, respiratory syncytial virus, legionella, and mononucleosis were negative. Cultures of tracheal aspirates were sterile for *Pseudomonas aeruginosa* and for methicillin-resistant *Staphylococcus aureus*. Cultures of nasal swabs also showed no growth of methicillin-resistant *S. aureus.* Nasopharyngeal swab tested positive for COVID-19 infection by nucleic acid amplification which was confirmed by polymerase chain reaction. Multiple blood cultures were sterile. Tests for *Clostridium difficile* toxin A and B and stool examinations for ova and parasites were negative. Stool cultures revealed no intestinal pathogens. Fecal calprotectin and lactoferrin levels were within normal limits.

She received vigorous fluid resuscitation, replacement of depleted electrolytes, insulin, and oxygen at 2 L via nasal cannulae. Chest roentgenogram 2 days later showed confluent right and left lung opacities. She required intubation and mechanical ventilation 2 days later for severe hypoxemia. Her ferritin rose to 991 ng/mL (normal: 12--207 ng/mL). She continued to have significant diarrhea. Her leukocyte count became 29,000 bil/L. She was empirically administered broad spectrum antibiotics. She developed progressive renal failure with creatinine rising to 3.75 mg/dL, and estimated glomerular filtration rate of 16 mL/min/1.73 m^2^ (normal \> 90, severely decreased: 15--29) requiring continuous renal replacement therapy. Lactic acid was 2.9 mmol/L (normal 0.5--2.2 mmol/L). She had no gross gastrointestinal bleeding and no rise in liver function tests. She died 3 days later from progressive respiratory and renal failure.

Patient presented with multiple electrolyte abnormalities (hypokalemia and hyponatemia) and multiple physical signs of dehydration attributed to moderately severe diarrhea (before developing significant pulmonary signs) which likely contributed to the early renal insufficiency that relentlessly progressed to renal failure. The diarrhea in COVID-19 infection might be related to gastrointestinal infection by the virus ([@R2]).
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